Compare LOCL & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOCL | COEP |
|---|---|---|
| Founded | 2021 | 2017 |
| Country | United States | United States |
| Employees | 333 | 7 |
| Industry | Farming/Seeds/Milling | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.6M | 72.7M |
| IPO Year | N/A | N/A |
| Metric | LOCL | COEP |
|---|---|---|
| Price | $1.11 | $12.04 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 23.0K | ★ 32.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $36.93 | N/A |
| Revenue Next Year | $82.62 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.98 | $6.32 |
| 52 Week High | $5.75 | $21.41 |
| Indicator | LOCL | COEP |
|---|---|---|
| Relative Strength Index (RSI) | 29.32 | 45.69 |
| Support Level | $0.98 | $10.98 |
| Resistance Level | $2.75 | $13.23 |
| Average True Range (ATR) | 0.13 | 0.94 |
| MACD | -0.00 | 0.08 |
| Stochastic Oscillator | 22.18 | 41.06 |
Local Bounti Corp is a controlled environment agriculture company. Its business model is based on building local facilities, operated by local teams, to deliver fresh and quality produce to local communities while maintaining a limited carbon footprint. Using proprietary technology to grow leafy greens and herbs in smart greenhouses with a cultivation process that uses less water and land than conventional agriculture, free from herbicides or pesticides, it delivers products that have a longer shelf life, and are good in taste.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.